Zevra Sells Rare Pediatric Disease Priority Review Voucher for $150 Million
Deal News | Feb 27, 2025 | Globenewswire
Zevra Therapeutics, a commercial-stage company specializing in rare diseases, has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher for $150 million. The transaction aims to bolster Zevra's financial position and supports its strategic priorities, including the commercial launches of MIPLYFFA and OLPRUVA. The PRV sale is anticipated to close within 30 to 45 days, subject to typical closing conditions, including an antitrust review. This strategic move comes after the PRV was awarded following the FDA's approval of MIPLYFFA. Cantor Fitzgerald assisted as the exclusive financial advisor and Latham & Watkins LLP as the legal advisor for the transaction.
Sectors
- Pharmaceuticals
- Healthcare
Geography
- United States – Zevra Therapeutics is based in Celebration, Florida, and the transaction involves regulatory approval from the U.S. FDA.
Industry
- Pharmaceuticals – Zevra Therapeutics operates within the pharmaceutical industry, focusing on treatments for rare diseases.
- Healthcare – The article discusses Zevra's activities in developing therapies for rare diseases, a core area within the healthcare sector.
Financials
- $150 million – The gross proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Zevra Therapeutics, Inc. | Target company | Company | A commercial-stage company providing therapies for people living with rare diseases. |
| Cantor Fitzgerald | Financial advisor | Company | Acted as Zevra's exclusive financial advisor for the PRV sale transaction. |
| Latham & Watkins LLP | Legal advisor | Company | Provided legal advice to Zevra for the PRV sale transaction. |
| LaDuane Clifton | Chief Financial Officer | Person | CFO of Zevra Therapeutics, involved in announcing the agreement. |